Reported 1 day ago
JPMorgan has reduced its price target for Immunovant, Inc. (IMVT) from $37 to $33 while maintaining an Overweight rating. The firm noted that Immunovant's cash reserves of approximately $598.9 million support its upcoming drug developments aimed at treating autoimmune diseases. However, the analyst suggests that there may be more promising investment opportunities in the AI sector.
Source: YAHOO